A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment
Phase: PHASE2 | Sponsor: NYU Langone Health | Compound: Psilocybin
- Status
- recruiting
- Institution
- NYU Langone Health
- Start date
- 2025-08-01
- End date
- 2029-02-01
- Registry ID
- NCT06796062
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.